Stocks · News reference
GlucoTrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To One
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 9:34 PM
- Checked
- Jul 29, 2026, 9:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Glucotrack, Inc. (GCTK)
Filed: 2026-08-27 AccNo: 0001493152-26-040332 Size: 230 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarGlucotrack Announces 1-For-15 Reverse Stock Split Effective August 31
Read original at benzingaGlucotrack's Lōkahi Therapeutic Subsidiary Initiates Good Manufacturing Practice Production Campaign For LT-100
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the
Read original at benzinga